Two more suspended at RBS.
Wall Street loves a murder metaphor.
In his autobiography Rogue Trader, Nick Leeson said the ethos at Barings was simple: ‘We were all driven to make profits, profits, and more profits ... I was the rising star.’
Sitting at her desk at Goldman Sachs, Julissa Arce is doing her best to keep it together. It’s September 2007. Her father is dying in Taxco de Alarcón, a small and hilly city in Mexico, and she has just hung up after a call from her sister with bad news.
Longstanding allegations that women are routinely discriminated against in Silicon Valley were being aired in open court on Tuesday when a former venture capital executive began a $16m sexual discrimination lawsuit against top tech investor Kleiner Perkins Caufield & Byers.
Royal Bank of Scotland will outline plans Thursday to reduce the number of countries in which it operates by two-thirds to 13, a person with knowledge of the matter said.
"Our synergies are real," said Marianne Lake, pointing to some $15 billion in revenue and $3 billion in cost savings due to its business model.
Bank of America’s Henry Mulholland, head of equities for the Americas and a 25-year veteran of Merrill Lynch, is leaving the firm.
Royal Bank of Scotland could be broken up into 130 locally run banks and operated along the principle of the John Lewis Partnership rather than be privatised by the next government, according to a report published on Wednesday.
BHP Billiton plans to make further big cuts in spending, blaming a sharp fall in profits on the plummeting price of oil and other commodities.
BNP Paribas became the latest bank to be dragged into a spate of foreign-exchange-related employment lawsuits after its former head of spot currency trading sued the lender.
Malaysia must open a probe into the former boss of 1Malaysia Development Berhad (1MDB), a Malaysian parliamentary committee said on Thursday, after the committee's own investigation found "restrictions and weaknesses" at the troubled wealth fund.
Barack Obama’s derailment of Pfizer’s $160bn (£114bn) merger with Allergan sparked immediate speculation on Wednesday that the US drugs company would turn its attention to another big pharmaceutical takeover.